Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

179.25USD
30 Sep 2016
Change (% chg)

$2.81 (+1.59%)
Prev Close
$176.44
Open
$177.02
Day's High
$179.29
Day's Low
$177.02
Volume
526,338
Avg. Vol
813,968
52-wk High
$181.76
52-wk Low
$129.50

Latest Key Developments (Source: Significant Developments)

BD submits pre-market approval application to FDA for BD Onclarity™ HPV test
Tuesday, 6 Sep 2016 06:59am EDT 

Becton Dickinson And Co :Says intends to ultimately seek approval using HPV genotyping beyond 16, 18 and 45.  Full Article

Becton Dickinson declares quarterly dividend 66 cents/shr
Tuesday, 26 Jul 2016 04:15pm EDT 

Becton Dickinson And Co :Declared a quarterly dividend of 66 cents per common share, payable on september 30, 2016.  Full Article

BD and check-points announce development and global distribution agreement for BD MAX
Thursday, 16 Jun 2016 06:59am EDT 

Becton Dickinson And Co :BD and check-points announce development and global distribution agreement for BD MAX(TM) assays that detect carbapenem-resistant organisms.  Full Article

B.Braun Medical and affiliates sue Becton, Dickinson & Co for patent infringements
Monday, 6 Jun 2016 05:10pm EDT 

B. Braun Medical Inc [BBRMG.UL] : B. Braun Medical Inc and affiliates sue Becton, Dickinson & Co. For IV catheter safety mechanism patent infringements .Co, affiliates filed lawsuit against Becton, Dickinson, unit for infringing 10 U.S. patents relating to IV catheter safety mechanisms.  Full Article

Becton Dickinson received CE mark for BD MAX Vaginal Panel
Friday, 13 May 2016 07:55am EDT 

Becton Dickinson And Co :Obtained CE mark for BD MAX Vaginal Panel.  Full Article

Becton Dickinson and Co updates FY 2016 revenue guidance and raises FY 2016 EPS guidance
Thursday, 5 May 2016 06:00am EDT 

Becton Dickinson and Co:Continues to estimate that currency-neutral adjusted revenues for FY 2016.Including the impact of foreign currency, as adjusted and as reported revenues are now expected to increase 21.5 to 22.0 pct for FY 2016.Continues to estimate organic adjusted revenues to increase 4.5 to 5.0 pct for FY 2016.Raised FY 2016 adjusted diluted earnings per share guidance to be between $8.50 and $8.57.  Full Article

Becton Dickinson and Co and Apax to form JV for respiratory solutions
Tuesday, 8 Mar 2016 08:30am EST 

Becton Dickinson and Co:Bd, apax partners to form joint venture for respiratory solutions.Announced definitive agreement to sell 50.1 percent of its respiratory solutions business to funds advised by apax partners.Says bd expects an immaterial impact to its fiscal year 2016 guidance from jv.In fiscal year 2017, bd anticipates earnings dilution of approximately $0.10 to $0.14.Says bd will retain 49.9 percent of the company as a significant but non-controlling minority owner.  Full Article

Becton Dickinson and Co receives FDA approval for new automated cervical Cancer Screening System
Monday, 7 Mar 2016 06:59am EST 

Becton Dickinson and Co:Says has received U.S. Food and Drug Administration (FDA) approval for its BD Totalys(tm) MultiProcessor and BD Totalys(tm) SlidePrep instruments.  Full Article

Becton Dickinson and Co gives FY 2016 guidance
Wednesday, 3 Feb 2016 06:00am EST 

Becton Dickinson and Co:Continues to estimate that currency-neutral adjusted revenues for FY 2016, including accretion from acquisition of CareFusion, will increase 24.5 to 25.0 percent. Including the impact of foreign currency, as adjusted and as reported, revenues are now expected to increase 20.0 to 20.5 percent.Says this is a decrease from previously issued guidance of 23.0 to 23.5 percent growth.On a comparable, currency-neutral basis, the company continues to estimate organic adjusted revenues will increase 4.5 to 5.0 percent.Continues to expect adjusted diluted earnings per share to be between $8.37 and $8.44 for FY 2016 including estimated unfavorable impact from foreign currency.Says on a currency-neutral basis, the company now expects FY 2016 adjusted diluted earnings per share to be between $9.01 and $9.08, which represents growth of about 26.0 to 27.0 percent over FY 2015 adjusted diluted earnings per share of $7.16.Says this is an increase from previously issued currency-neutral guidance of $8.73 to $8.80 which represented approximately 22.0 to 23.0 percent growth.As reported, the Company expects full fiscal year diluted earnings per share to be between $6.23 and $6.30.  Full Article

Becton Dickinson and Co divests BD Rx Business
Friday, 8 Jan 2016 08:05am EST 

Becton Dickinson and Co:Says Fresenius Kabi USA has acquired the BD Rx business.Additional financial and contractual terms of the transactions were not disclosed.BD and Fresenius Kabi have also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions.Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.Expects the divestiture of BD Rx to be modestly accretive to fiscal 2016 adjusted diluted earnings per share.  Full Article